Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Daniel Vt CatenacciYoon-Koo KangHope E UronisKeun-Wook LeeMatthew Ch NgPeter C EnzingerSe Hoon ParkPhilip J GoldJill LacyHoward S HochsterSang Cheul OhYeul Hong KimKristen A MarroneRonan J KellyRosalyn A JuergensJong Gwang KimThierry AlcindorSun Jin SymEun-Kee SongCheng Ean CheeYee ChaoSunnie KimDo-Youn OhJennifer YenJustin I OdegaardErrin LagowDaner LiJichao SunPatrick KaminkerPaul A MooreMinori Koshiji RosalesHaeseong ParkPublished in: Oncology (Williston Park, N.Y.) (2023)
Current ERBB2 status may be more effective than archival status at predicting clinical benefit from margetuximab plus pembrolizumab therapy. ctDNA testing for ERBB2 status prior to treatment will spare patients from repeat tissue biopsies, which may be reserved for reflex testing when ctDNA is not detected.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- end stage renal disease
- ejection fraction
- chronic kidney disease
- tyrosine kinase
- newly diagnosed
- advanced non small cell lung cancer
- squamous cell carcinoma
- prognostic factors
- radiation therapy
- patient reported outcomes
- mesenchymal stem cells
- single molecule
- epidermal growth factor receptor
- replacement therapy